Lenvatinib specifically is a multikinase inhibitor of VEGFR1, VEGFR2, & VEGFR3, and other receptor tyrosine kinases, although the drug Pembrolizumab is an antibody targeting PD-1. Combination of pembrolizumab and lenvatinib is used to treat a certain type of cancer of the endometrium (lining of the uterus) that has spread to other organs of the body or that can't be treated through surgery or radiation therapy.
The recommended dose of this combination drug therapy should be administered as per the words given by a healthcare professional.